Curis Provides Third Quarter 2024 Business Update

Management to host conference call today at 8:30 a.m. ETLEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024."We continue to make excellent progress across our clinical programs. We are especially excited about the recent R/R PCNSL data released in Se ...